Hong Kong Stock Movement: ETHK LABS INC. rises 15.13%, new Chief Scientist and AI trends boost stock price surge

Hong Kong Stock Movement HuaJian Medical rose by 15.13%. Based on recent key news: On February 9, HuaJian Medical announced that Ms. Yi Xiao was appointed as Executive Director and Chief Scientist. This appointment is seen as a strategic enhancement for the company in the fields of translational medicine and biomaterials, driving the stock price up. On February 9, a report from ARK Invest pointed out that the combination of AI and multi-omics is driving biological innovation, and HuaJian Medical is at the intersection of this trend, further enhancing market expectations for its future growth. On February 6, analysts gave HuaJian Medical a latest rating of Hold, with a target price of HKD 1.50. Despite technical signals indicating a sell, the market's positive response to the company's strategic adjustments has driven the stock price up. Risks need to be monitored as the AI medical ecosystem is being constructed. Stocks with High Trading Volume in the Industry China National Pharmaceutical Group, down 0.28%, with a trading volume of HKD 41.69 million, has no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, this stock shows significant volatility, and specific reasons need further observation. Health 160, up 1.79%, with a trading volume of HKD 21.08 million, has no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, this stock shows significant volatility, and specific reasons need further observation. Shanghai Pharmaceuticals, down 0.42%. Based on recent news: On February 5, Shanghai Pharmaceuticals disclosed that the performance of its joint venture with Bristol-Myers Squibb continues to decline, with net profit shrinking to HKD 87 million in the first three quarters of 2025. The decline in performance is mainly due to core products failing to win bids in the national drug procurement, with market share being eroded by generic drugs. The parent company BMS is under pressure, selling 60% of its stake in the joint venture, further exacerbating market concerns about Shanghai Pharmaceuticals. On February 7, results from a Phase II trial presented at the International Stroke Conference showed that LT3001 has significant functional improvement effects for patients with acute ischemic stroke. Although this news has a positive impact on the overall industry, it has not been able to offset the negative news for Shanghai Pharmaceuticals. No other significant news recently. The pharmaceutical industry is facing overall pressure from centralized procurement, with intensified market competition. Stocks with High Market Capitalization in the Industry Baiyunshan, down 0.78%. Based on recent key news: On February 6, Baiyunshan's subsidiary Xingqun Pharmaceutical received a notice of approval from the National Medical Products Administration, indicating that Alfacalcidol soft capsules have passed the consistency evaluation of quality and efficacy for generic drugs. This news may have a positive impact on the company's future drug sales, but it has not immediately driven the stock price up. Source: People's Financial News, Zhitong Finance. Significant policy changes in the pharmaceutical industry recently